These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 34626838)

  • 1. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M
    J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
    Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M
    J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
    N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
    Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA
    J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
    Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
    Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
    Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
    Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
    Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
    Dhillon S; Syed YY
    Target Oncol; 2019 Dec; 14(6):759-768. PubMed ID: 31728860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Zhou Y; Guo T; Liang F; Wang Z; Zhang J; Ni J; Zhu Z
    Cancer; 2024 Aug; 130(15):2601-2610. PubMed ID: 38353467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
    Bodor JN; Patel JD; Wakelee HA; Levy BP; Borghaei H; Pellini B; Costello MR; Dowell JE; Finley G; Huang CH; Neal JW; Nieva JJ; Puri S; Socinski MA; Thomas C; Ross EA; Litwin S; Clapper ML; Treat J
    Clin Lung Cancer; 2023 Nov; 24(7):e242-e246. PubMed ID: 37451930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
    Socinski MA; Jotte RM; Cappuzzo F; Nishio M; Mok TSK; Reck M; Finley GG; Kaul MD; Yu W; Paranthaman N; Bara I; West HJ
    JAMA Oncol; 2023 Apr; 9(4):527-535. PubMed ID: 36795388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
    Trummer A; Bethge A; Dickgreber N; Dittrich I; Golpon H; Hoffknecht P; Overbeck TR; Wesseler C; Reck M
    Lung Cancer; 2022 Dec; 174():141-145. PubMed ID: 36402005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.